Incyte announces results from its Phase 1 studies of INCA33890, INCB161734

Incyte (INCY) announced that results from Phase 1 proof-of-concept studies of INCA33890, a TGFbetaR2PD-1-directed bispecific antibody, and INCB161734, a novel, selective and orally bioavailable KRAS G12D inhibitor, will be highlighted as oral presentations at the upcoming European Society of Medical Oncology, ESMO, Congress 2025 in Berlin. “We are encouraged by the positive findings being presented with our TGFbetaR2PD-1 and KRAS G12D inhibitor programs, which validate our rationale for advancing the development of these novel investigational compounds,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “There remains a significant need for new treatment options for patients with advanced solid tumors like colorectal cancer and pancreatic ductal adenocarcinoma and we look forward to providing updates on these clinical development programs.”